Catalent is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD to support a growing customer pipeline and market demand. The campus in Harmans, near the Baltimore Washington International (BWI) airport, comprises two state-of-the-art facilities that, when completed, will house a total of 15 gene therapy suites each designed to accommodate multiple bioreactors for commercial supply. The first Harmans/BWI...